Cerity Partners LLC Has $580,000 Stock Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Cerity Partners LLC raised its holdings in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 122.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,821 shares of the company's stock after buying an additional 14,195 shares during the quarter. Cerity Partners LLC's holdings in Privia Health Group were worth $580,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRVA. Loomis Sayles & Co. L P lifted its position in shares of Privia Health Group by 55.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,418,234 shares of the company's stock worth $27,727,000 after acquiring an additional 503,002 shares during the period. Durable Capital Partners LP lifted its position in shares of Privia Health Group by 3.4% during the 4th quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company's stock worth $224,587,000 after buying an additional 378,255 shares during the period. BlackBarn Capital Partners LP lifted its position in shares of Privia Health Group by 65.8% during the 4th quarter. BlackBarn Capital Partners LP now owns 663,397 shares of the company's stock worth $12,969,000 after buying an additional 263,397 shares during the period. Nuveen Asset Management LLC lifted its position in shares of Privia Health Group by 19.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,488,979 shares of the company's stock worth $29,110,000 after buying an additional 246,393 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in shares of Privia Health Group during the 4th quarter worth approximately $4,321,000. Institutional investors and hedge funds own 94.48% of the company's stock.

Insider Transactions at Privia Health Group

In related news, Director Matthew Shawn Morris sold 10,309 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $240,508.97. Following the completion of the transaction, the director directly owned 59,792 shares of the company's stock, valued at approximately $1,394,947.36. This represents a 14.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David Mountcastle sold 3,445 shares of the stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $80,371.85. Following the transaction, the chief financial officer directly owned 176,231 shares of the company's stock, valued at $4,111,469.23. This trade represents a 1.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,949 shares of company stock valued at $1,100,368 over the last three months. Company insiders own 10.70% of the company's stock.

Privia Health Group Price Performance

Shares of PRVA stock remained flat at $19.70 on Friday. The stock had a trading volume of 784,411 shares, compared to its average volume of 968,080. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 164.18, a P/E/G ratio of 3.15 and a beta of 0.82. The business has a fifty day moving average of $22.06 and a 200-day moving average of $22.95. Privia Health Group, Inc. has a 52 week low of $16.47 and a 52 week high of $26.09.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PRVA shares. JMP Securities reaffirmed a "market outperform" rating and issued a $29.00 target price on shares of Privia Health Group in a report on Monday, April 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 target price on shares of Privia Health Group in a report on Thursday, April 10th. JPMorgan Chase & Co. upped their target price on shares of Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a report on Wednesday, May 28th. Robert W. Baird upped their target price on shares of Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a report on Tuesday, April 15th. Finally, Truist Financial lifted their price objective on Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $28.38.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.